Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 3. Changes from baseline in activated CD4<sup>+</sup> T cells (% CD4<sup>+</sup>CD25<sup>+</sup>) during the 52-week intervention period in the.

Published byJoan Stokes Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 3. Changes from baseline in activated CD4<sup>+</sup> T cells (% CD4<sup>+</sup>CD25<sup>+</sup>) during the 52-week intervention period in the."— Presentation transcript:

1 Figure 3. Changes from baseline in activated CD4<sup>+</sup> T cells (% CD4<sup>+</sup>CD25<sup>+</sup>) during the 52-week intervention period in the intention-to-treat population from a BITE pilot study (*P = .036, change from baseline). The Immunomodulatory Nutritional Intervention NR Reduced CD4+ T-Cell Decline and Immune Activation: A 1-Year Multicenter Randomized Controlled Double-Blind Trial in HIV-Infected Persons Not Receiving Antiretroviral Therapy (The BITE Study) Clin Infect Dis. 2013;57(1): doi: /cid/cit171 Clin Infect Dis | © The Author Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please 1

Download ppt "Figure 3. Changes from baseline in activated CD4<sup>+</sup> T cells (% CD4<sup>+</sup>CD25<sup>+</sup>) during the 52-week intervention period in the."

Similar presentations

To enhance students ability to interpret data in charts and graphs To discuss basic concepts in epidemiology and science.

To enhance students ability to interpret data in charts and graphs To discuss basic concepts in epidemiology and science.
From: An open day in the metric space

From: An open day in the metric space
Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.

Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.
Fig. 1 Flow chart of the COBRA-light trial and its extension study

Fig. 1 Flow chart of the COBRA-light trial and its extension study
Figure 1 The spatial and temporal distribution of diarrhoea rates

Figure 1 The spatial and temporal distribution of diarrhoea rates
Figure 1. Flow diagram of participants recruited into the study.

Figure 1. Flow diagram of participants recruited into the study.
Figure 2. Quality of life (QOL) scores for functional scale items

Figure 2. Quality of life (QOL) scores for functional scale items
Figure 1. Scree plot for the exploratory factor analysis (EFA) of the Death Depression Scale (DDS). From: Development and psychometric evaluation of a.

Figure 1. Scree plot for the exploratory factor analysis (EFA) of the Death Depression Scale (DDS). From: Development and psychometric evaluation of a.
Figure 2. CONSORT flow diagram.

Figure 2. CONSORT flow diagram.
Figure 1. Period–cohort diagram.

Figure 1. Period–cohort diagram.
From: Political Leadership and Power Redistribution

From: Political Leadership and Power Redistribution
Figure 1. The Modified Dual Pathway Model.

Figure 1. The Modified Dual Pathway Model.
Figure 1. Disposition of study participants, by group. Data are no

Figure 1. Disposition of study participants, by group. Data are no
Figure 1. Structural Equation Model: Effects of Valence Framing on Perceived Truth of Statements and Source Trustworthiness. Standardized path-coefficients.

Figure 1. Structural Equation Model: Effects of Valence Framing on Perceived Truth of Statements and Source Trustworthiness. Standardized path-coefficients.
Figure 1. Forest plot: overall estimate

Figure 1. Forest plot: overall estimate
Table 5 Village Characteristics Based on the Census of India 1991, by Mandate during which a First SHG was Created in the Village From: Public Good Provision.

Table 5 Village Characteristics Based on the Census of India 1991, by Mandate during which a First SHG was Created in the Village From: Public Good Provision.
Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine;

Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine;
Figure 1. Mean recalled time (days) since the start of the last quit attempt by use of stop-smoking medications (SSM) and Heaviness of Smoking Index (HSI)

Figure 1. Mean recalled time (days) since the start of the last quit attempt by use of stop-smoking medications (SSM) and Heaviness of Smoking Index (HSI)
Error bars represent the mean (s.e.).

Error bars represent the mean (s.e.).
Figure 1. Shiga toxin–producing Escherichia coli (STEC) isolates by method of initial detection and STEC serotype, Connecticut, 2000–2009. From: Ten-Year.

Figure 1. Shiga toxin–producing Escherichia coli (STEC) isolates by method of initial detection and STEC serotype, Connecticut, 2000–2009. From: Ten-Year.

Similar presentations

Ads by Google